CSIMarket
 
Sutro Biopharma Inc   (STRO)
Other Ticker:  
 
 
Price: $3.9100 $-0.20 -4.866%
Day's High: $4.09 Week Perf: -11.74 %
Day's Low: $ 3.88 30 Day Perf: -12.92 %
Volume (M): 975 52 Wk High: $ 6.11
Volume (M$): $ 3,810 52 Wk Avg: $4.25
Open: $4.09 52 Wk Low: $2.01



 Market Capitalization (Millions $) 237
 Shares Outstanding (Millions) 61
 Employees -
 Revenues (TTM) (Millions $) 49
 Net Income (TTM) (Millions $) -172
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Sutro Biopharma Inc
Sutro Biopharma Inc is a clinical-stage company that specializes in developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer. The company utilizes its proprietary technology called cell-free protein synthesis to design and develop novel ADCs with improved efficacy and safety profiles.

Sutro Biopharma's platform enables them to rapidly discover and manufacture ADCs in a highly efficient manner, resulting in a faster timeline from discovery to development. The company has a diverse pipeline of potential therapies targeting various types of cancer, including solid tumors and hematologic malignancies.

The goal of Sutro Biopharma is to transform the treatment landscape for cancer patients by delivering potent and targeted therapies that have the potential to improve outcomes and minimize side effects. They collaborate with pharmaceutical companies and academic institutions to advance their pipeline and leverage their technology for the development of novel therapies.

Sutro Biopharma is committed to innovation, and their unique approach to ADC development sets them apart in the biopharmaceutical industry. With a team of experienced scientists and researchers, the company aims to bring transformative therapies to patients in need.


   Company Address: 111 Oyster Point Blvd South San Francisco 94080 CA
   Company Phone Number: 881-6500   Stock Exchange / Ticker: NASDAQ STRO
   STRO is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Sutro Biopharma's Revenue Dip Overshadowed by Strides in Pediatric Leukemia Treatment: Luveltamab Tazevibulin's Promise Amid Fiscal Storms

Published Mon, Dec 11 2023 9:06 PM UTC


Luveltamab Tazevibulin, more commonly known as luvelta, exhibited complete remission in 42% of patients with CBF/GLIS Acute Myeloid Leukemia (AML) having 5% blasts, while an impressive 75% remission rate was noted in pediatric patients suffering from the same condition with less than 5% blasts. The remission occurred whether luvelta was used as a standalone therapy or i...

Sutro Biopharma Inc

Sutro Biopharma Inc Faces Widening Diminishing Returns in Financial Q3 2023

For the financial third quarter of 2023, Sutro Biopharma Inc (STRO) experienced an increased loss per share of $-0.81 compared to $-0.37 in the same period last year. This loss also represented a surge from the preceding financial reporting period, where the loss per share was $-0.64. These figures indicate a decline in profitability for the company.
Furthermore, the company's revenue also saw a decline of -32.7% to $16.92 million from $25.15 million in the comparative financial reporting period a year ago. However, sequentially, there was a significant increase in revenue of 62.543% from $10.41 million.

Sutro Biopharma Inc

Sutro Biopharma Inc's Financial Troubles Continue to Deepen, Raising Concerns about the Company's Future

In the face of disappointing financial results, Sutro Biopharma Inc. is witnessing a downward spiral that is casting serious doubt on the company's future prospects. The company's April to June 2023 quarter was nothing short of disastrous as its revenue plummeted by a staggering -62.941% to a mere $10.41 million, compared to the same period last year. This significant decline indicates that Sutro Biopharma is failing to generate sufficient revenue to sustain its operations.
Adding to the pessimism, Sutro Biopharma's earnings per share (EPS) shortfall widened to -$0.64 from the previous year's -$0.85, exhibiting a clear negative trend. This decline can be attributed to a combination of factors, including poor performance, ineffective cost management, and a lack of strategic direction.

Sutro Biopharma Inc

Sutro Biopharma Inc Reports Impressive Revenue Growth in Q1 2023, But Also Experiences Increased Losses

Sutro Biopharma Inc, a company that specializes in developing innovative cancer therapies, has recently released its financial results for the first quarter of 2023. The report indicates an impressive revenue growth of 114.923% year on year to $12.67 million. This is great news for the company as it demonstrates that their efforts to commercialize their products are paying off. However, the company also reported an increased loss per share at $-0.85, which is higher than last year's $-0.55 per share. This shows that the company is still investing heavily in research and development to develop its innovative cancer therapies.
The revenue for the first quarter of 2023 surged by 46.826% compared to the previous reporting season, where the company generated $8.63 million. This increase in revenue can be attributed to the company's growing customer base and increased sales of its products. However, Sutro Biopharma attracted a bigger net loss of $-50.050 million for the current quarter, compared with $-39.110 million a year ago. The increase in loss might be a result of the company's investments in several projects that are still in the pre-clinical stage, and hence, still far from generating revenue.






 

Sutro Biopharma Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com